Evidence map›Paper›PMID 32641579›Full record

ArticleJCI insight2020

MYSM1 maintains ribosomal protein gene expression in hematopoietic stem cells to prevent hematopoietic dysfunction.

Jad I Belle, HanChen Wang, Amanda Fiore, Jessica C Petrov, Yun Hsiao Lin, Chu-Han Feng, Thi Tuyet Mai Nguyen, Jacky Tung, Philippe M Campeau, Uta Behrends and 5 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Genetic influences on haematopoiesis.Nature reviews. Genetics · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma.Journal of cellular and molecular medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 5 countries.

Jad I BelleDepartment of Physiology.
HanChen WangDepartment of Physiology.
Amanda FioreDepartment of Physiology.
Jessica C PetrovDepartment of Physiology.
Yun Hsiao LinDepartment of Physiology.
Chu-Han FengDepartment of Physiology.
Thi Tuyet Mai NguyenCentre Hospitalier Universitaire St. Justine Research Center, University of Montreal, Quebec, Canada.
Jacky TungDepartment of Physiology.
Philippe M CampeauCentre Hospitalier Universitaire St. Justine Research Center, University of Montreal, Quebec, Canada.
Uta BehrendsChildrens' Hospital and.
Theresa BrunetInstitute of Human Genetics, Technische Universität München (TUM), Munich, Germany.
Gloria Sarah LeszinskiInstitute of Human Genetics, Technische Universität München (TUM), Munich, Germany.
Philippe GrosMcGill University Research Centre on Complex Traits, and.
David LanglaisMcGill University Research Centre on Complex Traits, and.
Anastasia NijnikDepartment of Physiology.
Czech Academy of Sciences, Institute of Physiology · CZCentre Hospitalier Universitaire Sainte-Justine · CAChildren's Hospital · TNHelmholtz Zentrum München · DEInstitute of Human Genetics · PLMcGill Genome Centre · CAMcGill University Health Centre · CA

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
CIHR MOP-123403CIHR PJT-153016NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Ribosomopathies are congenital disorders caused by mutations in the genes encoding ribosomal and other functionally related proteins. They are characterized by anemia, other hematopoietic and developmental abnormalities, and p53 activation. Ribosome assembly requires coordinated expression of many ribosomal protein (RP) genes; however, the regulation of RP gene expression, especially in hematopoietic stem cells (HSCs), remains poorly understood. MYSM1 is a transcriptional regulator essential for HSC function and hematopoiesis. We established that HSC dysfunction in Mysm1 deficiency is driven by p53; however, the mechanisms of p53 activation remained unclear. Here, we describe the transcriptome of Mysm1-deficient mouse HSCs and identify MYSM1 genome-wide DNA binding sites. We establish a direct role for MYSM1 in RP gene expression and show a reduction in protein synthesis in Mysm1-/- HSCs. Loss of p53 in mice fully rescues Mysm1-/- anemia phenotype but not RP gene expression, indicating that RP gene dysregulation is a direct outcome of Mysm1 deficiency and an upstream mediator of Mysm1-/- phenotypes through p53 activation. We characterize a patient with a homozygous nonsense MYSM1 gene variant, and we demonstrate reduced protein synthesis and increased p53 levels in patient hematopoietic cells. Our work provides insights into the specialized mechanisms regulating RP gene expression in HSCs and establishes a common etiology of MYSM1 deficiency and ribosomopathy syndromes.

Indexed as

AnimalsCell DifferentiationGene ExpressionHematopoiesisHematopoietic Stem CellsHistonesMice, TransgenicRibosomal ProteinsTrans-ActivatorsUbiquitin-Specific ProteasesHistonesMYSM1 protein, mouseRibosomal ProteinsTrans-ActivatorsUbiquitin-Specific ProteasesHematologyHematopoietic stem cellsStem cells

Identifiers

PMID32641579
PMCPMC7406308
OpenAlexW3040761286

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.